-+ 0.00%
-+ 0.00%
-+ 0.00%

In early trading on Monday, shares of clinical-stage biopharmaceutical company Syndax fell 3.2%. The company presented the latest data on its acute leukemia drug revimenil combination therapy at the 2025 American Society of Hematology annual meeting, showing high remission rates and high negative rates of minor residual disease in a cohort of newly diagnosed and post-transplant acute myeloid leukemia patients.

Zhitongcaijing·12/08/2025 15:49:07
Listen to the news
In early trading on Monday, shares of clinical-stage biopharmaceutical company Syndax fell 3.2%. The company presented the latest data on its acute leukemia drug revimenil combination therapy at the 2025 American Society of Hematology annual meeting, showing high remission rates and high negative rates of minor residual disease in a cohort of newly diagnosed and post-transplant acute myeloid leukemia patients.